The Cancer Letter

Inside information on cancer research and drug development

In Brief

CPRIT approves nearly $99M in grants

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The governing body of the Cancer Prevention and Research Institute of Texas, or CPRIT, approved $98,592,155 in grants to focus on cancer in Texas. The grants are a mix of academic research and prevention projects and represents the largest public state commitment to cancer research by any U.S. state.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

NCI Director's Report

As NCI’s appropriations stay flat, Rathmell keeps the FY26 bypass budget steady at just under $11.5B
Rathmell: “We understand that there are real economic constraints facing our country and the world. But our gap just can’t keep widening.”

NCI Director Kimryn Rathmell has released her professional judgment budget proposal, requesting nearly $11.5 billion—the same amount as last year’s proposal prepared by her predecessor, Monica Bertagnolli.
By Jacquelyn Cobb
Capitol Hill

House GOP leaders propose “streamlining” NIH into 15 institutes and centers
Plan calls for slashing ARPA-H, adding oversight to infectious disease research

Two Republican leaders in the House of Representatives have published a “framework” for reforming NIH—consolidating the agency’s 27 institutes and centers into 15—arguing that a fundamental rethinking of NIH’s structure would fix what they describe as a “system rife with stagnant leadership, as well as research duplication, gaps, and misconduct.”
By Matthew Bin Han Ong
Table of Contents

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account